

**2023 ANNUAL REPORT**

**TAG**

Treatment Action Group

# **PROGRESS IN THE FIGHT**

For Better Treatment, Prevention,  
a Vaccine and a Cure for HIV,  
Tuberculosis, and Hepatitis C Virus




**JULY 2024**

## DEAR FRIENDS,

With the passing of the leadership mantle for TAG's board president role to the amazing Ivy Kwan Arce in early 2024, I am taking a moment to look back over 2023 and beyond to reflect on some key moments for TAG under my term.

When I became board president in 2021, we were all still reeling from the upheaval of the COVID-19 pandemic. The inequities of our local, national, and global health systems had been laid bare. Our staff and partners who work tirelessly to advance treatment, prevention, and scientific advances for those affected by HIV, tuberculosis (TB), and hepatitis C virus (HCV) had spent a year leveraging their expertise and dedication for an entirely new public health emergency. Set against the backdrop of growing anti-science sentiment and polarization, it was a challenging time, to say the least.

However, the TAG team rose to the occasion and adapted to these new challenges. Accessibility was improved through adoption of new technologies. Our staff grew ever more diverse in background, geography, and racial make-up. Our staff grew to a highwater mark of 21 full time staff members



Rob (left) at 2023's Research in Action Awards, with longtime TAG supporters Chris Kauffman, Dennis Giza, and Rob's husband, Mark Gilrain. Photo by Alan Barnett.

in 2023. I couldn't be prouder of our dedicated team! They are the reason TAG's work continues to be so necessary in today's world.

While I have stepped down from the board presidency, I am excited to remain a very active and engaged board member. I am also excited to see the new directions that Ivy will lead TAG in the coming months and years. It goes without saying, but I will say it one more time, each of you as committed TAG supporters, you are the final (and required) ingredient in our past, present, and future success. Each of you are responsible for every achievement TAG has made since our founding in 1992. Thank you!

**ROB LENNON**

***TAG Board Immediate Past President***

**JULY 2024**

## DEAR LOYAL TAG SUPPORTERS,

Following our annual board meeting in February, I was so pleased to accept the leadership role as TAG's board president. TAG, in many ways, has been a part of my life and my activism since its founding over three decades ago. Leading TAG's board is an honor that I take very seriously.

In 1992, I said to Sally Cooper, who was then director of the People with AIDS (PWA) Health Group, "I wish HIV-positive women could have a version of TAG." Treatment and access to clinical trials were often out of reach for us back then.

Over the last three years, TAG has given me the opportunity to work with the most dedicated and brilliant staff. Organizing with Richard Jefferys, who has helped me research options these last 33 years of dire health needs, including research support as I decided to become a parent 24 years ago — securing both my sons' HIV-free negative status has been incredible.

I have met global partners who continue to inform and shape the roadmap for a cure. I am intensely grateful to be part of TAG's work creating new and expanded places at the table that weren't available before TAG came into existence.

Since joining the board I've had the privilege of working closely with Rob which has given me a unique perspective on his leadership at both the macro and micro levels. His unwavering support for the staff and the mission, particularly during the challenging times brought about by COVID-19, has been a testament to his resilience. His dedication will continue to benefit TAG and his advice and guidance will help me support TAG effectively.



Ivy at 2023's Research in Action Awards with board member David Puente (middle) and his husband, Allan Arellano. Photo by Alan Barnett.

While this annual report is about looking back at the past year, I am as proud of TAG's recent accomplishments as I am hopeful for all the future work ahead of us. I hope you join us in support on this journey.

A handwritten signature in black ink, appearing to read 'Ivy Kwam Arce'.

**IVY KWAN ARCE**  
**TAG Board President**



# RESEARCH IN ACTION AWARDS

TAG's 2023 Research in Action Awards — our signature fundraiser of the year — took place on October 19 in New York City. In addition to **raising over \$240,000**, it was one of our most entertaining events in recent memory. Chaired (for the last time) by the indefatigable **Bob Bronzo**, the event was held at the beautiful Angel Orensanz Foundation and live-streamed for our supporters around the world. Our program kicked off at 6:00 p.m. with a cocktail hour, followed by a video from the ***Moulin Rouge! The Musical*** company members introducing our fabulous emcee, **Tamrin Goldberg**.

We honored **The Latino Commission on AIDS, Guillermo Chacón**; **The Sentinel Project on Pediatric Drug-Resistant Tuberculosis, Mercedes C. Becerra, ScD, Jennifer J. Furin, MD, PhD, and Soumya Swaminathan, MD**; and **Callen Lorde's Asa Radix, MD, PhD, MPH, FIDSA**.

We also auctioned off two tickets to *Moulin Rouge! The Musical*, and the bidding was extremely competitive. Board president **Ivy Kwan Arce** created this year's stunning Limited Art Edition, *Entre el cielo y la tierra* : 天地之間 東經134度 4分38秒, 北緯34度28分53秒. Finally, we closed the evening with a very special performance from two more *Moulin Rouge! The Musical* company members, DeAnne Stewart and John Cardoza.

**Be sure to save the date for our  
2024 Research and Action Awards  
on October 17!**



Emcee Tamrin Goldberg introduced herself and kicked off the program in style.



Honoree Guillermo Chacón (left) with the award for the Latino Commission on AIDS, which was presented by Jesus Aguais.



Outgoing RIAA event chair and now board member Bob Bronzo arrives at the podium.





Performers John Cardoza and DeAnne Stewart, who at the time were both *Moulin Rouge! The Musical* company members.



Mercedes Becerra (left) receives the award for The Sentinel Project from TAG's TB project co-directors, Lindsay McKenna and Mike Frick.



Board member David Puente (left) and his husband Allan Arellano with Acting HCV Director, Joelle Dountio Ofimboudem.



Karen Bronzo Rabb, long-time TAG supporter and sister of RIAA chair, Bob Bronzo, bidding in the auction for *Moulin Rouge! The Musical* tickets generously donated to TAG by the show.



Board president Rob Lennon and TAG's chief operating officer, Jason Kirk.



Honoree Dr. Asa Radix (left) after receiving his award from Peter Meacher.



Soumya Swaminathan and Jen Furin's video acceptances of the award for The Sentinel Project.



Kate O'Brien (left) of TAG ally We Are TB with Kendall Martinez-Wright, government relations & policy associate.



# TAG OUT & ABOUT



Chief operating officer Jason Kirk (in hat), basic science, vaccines, and cure project director Richard Jeffreys, and board president Ivy Kwan Arce, getting a tour of the Callen Lorde bus given by two staffers (in blue t-shirts).

For the past few years, TAG has co-sponsored the **LGBTQIA+ health fair** held during the Queer Liberation March in New York City. The fair offers support and resources related to queer sexual health, harm reduction, and affirming care and is organized by board member (and now board president) Ivy Kwan Arce.



Health fair organizer and TAG board president, Ivy Kwan Arce (in dress, center) with three volunteers at the ACT UP table.

In March and April, 2023, TAG presented the exhibition, “**35 Years of Art to End AIDS**” in Palm Desert, California at the Melissa Morgan Fine Art gallery. Pieces on display were selected Limited Art Editions. TAG board member and exhibition curator, Joy Episalla, created the beautiful show catalog and copies are still for sale. A special thank you to TAG board member, Kevin Goetz, for hosting this event and expanding TAG’s geographic reach.

*Photos from the exhibition are by James Bernal.*



TAG executive director, Mark Harrington, with TAG board member and event host Kevin Goetz.



Exhibition curator Joy Episalla, speaking about our 2021 Limited Edition (three shown here), “Bookmarks” (to her left) by Nancy Brooks Brody, who unfortunately passed away in 2023. On her right is Joy’s own Limited Art Edition from 2015, “Celestial Bodies, (40° 44’ N x 73° 59’ W), 1”.

In late summer, TAG board members Robert Monteleone and Laura Morrison hosted a **small dinner to connect with TAG Staff.**

Clockwise starting at right is David Branigan, TB project officer; Chris George, director of finance; Mark Harrington, executive director; Erin McConnell, senior TB project associate, and co-host, Robert Monteleone.





## PROGRAMS

# HIV PROJECT

Since TAG's 1992 founding, it has fought to end the HIV pandemic by engaging affected communities in research, implementation, policymaking, and activism.

TAG's basic science, vaccines, and cure project director Richard Jefferys spent much of 2023 applying his internationally recognized expertise in HIV immunology and research to community education efforts. He facilitated the annual HIV cure research workshop ahead of the Conference on Retroviruses and Opportunistic Infections (CROI), and he kept affected communities up to speed on key developments in HIV research via a webinar on AbbVie's HIV cure research portfolio, and through his widely cited HIV cure trials and demographic participation tracking tools. Jefferys also represented TAG at meetings with the Food and Drug Administration (FDA), urging action to close research gaps related to people living with HIV.

The HIV team frequently works to advance HIV research and policy interests. Project director Riko Boone serves as co-chair of the Federal AIDS Policy Partnership's (FAPP) Research Working Group, for which he co-organized a congressional briefing on HIV research. ACT NOW: END AIDS (ANEA) coalition director De'Ashia Lee conducted 17 advocacy visits to congressional staffers urging the passage of a National PrEP Program and the REPEAL Act to end HIV criminalization and facilitated a webinar featuring Tennessee-based advocates to strategize responses to the state's attack on federally funded HIV prevention programming. Closing out the year, in conjunction with southern partner organizations, ANEA co-hosted an inaugural *Southern Solidarity HIV Advocacy Summit*.


The fact that only 13% of Black Americans who could benefit from PrEP have accessed a prescription (compared to 94% of their white peers) motivates TAG's HIV project staff members' ongoing participation in the PrEP in Black America (PIBA) initiative, a Black-led



HIV project director, Riko Boone and ANEA director, De'Ashia Lee at the Southern Solidarity Advocacy Summit

advocacy coalition that aims to tackle systemic racism and other structural barriers to access lifesaving biomedical HIV prevention. Following the PIBA coalition's second summit in New Orleans, during the U.S. Conference on HIV/AIDS (USCHA) TAG helped launch the PIBA Activist Network, in solidarity with Black HIV advocacy leaders from Louisiana, the Atlanta Black Women Leaders on PrEP, AVAC, PrEP4All, and other partners.

TAG's work with the HIV Vaccine Trials Network (HVTN) focuses on reaching neglected populations. During USCHA, Boone and prior HIV Community Engagement Manager Abraham Johnson co-presented a workshop on *Centering Blackness in HIV Vaccine Research* and discussed how TAG's HIV Vaccine Social Media Ambassador initiative offers a new model for increasing awareness and influencing attitudes toward participation in HIV vaccine clinical trials. This paved the way for TAG, HVTN, and partner organizations to expand the reach of our collective programming as HIV vaccine research pivots to further explore the promise of broadly neutralizing antibodies (bNABs) as a novel approach to HIV prevention and treatment.



Basic science, vaccines, and cure project director Richard Jefferys, giving a pre-CROI workshop presentation

## PROGRAMS

# TB PROJECT

Since TAG brought tuberculosis (TB) into its mission in 2002, our advocacy has supported major scientific breakthroughs and made it possible to prevent and cure TB faster and more safely than ever before. While progress has been made, critical research gaps remain, and far too few communities have access to these advances.

Senior TB project officer David Branigan led TAG's involvement in the 1/4/6x24 Campaign, demanding universal implementation of the best available regimens — **one** month (or once weekly) for TB prevention, **four** months for drug-susceptible TB, and **six** months for drug-resistant TB — by the end of **2024**. To advance these goals, the TB team advocated for the inclusion of shorter regimens in Global Fund proposals, sent open letters to the diagnostics company Danaher/Cepheid calling for price drops on its rapid TB testing assays, and pushed for the inclusion of 1/4/6 regimens in UN member states' Political Declaration on TB and in the Lancet Commission on TB. The campaign, in partnership with Médecins Sans Frontières, Partners In Health, and bestselling author John Green, also compelled J&J to commit to not enforce its secondary patents on bedaquiline in 134 low- and middle-income countries, thus broadening access to this important TB drug.

The TB team demanded expanded and improved TB research: TB project co-director Mike Frick has emerged as a highly sought-after expert on TB vaccine research, presenting on the TB vaccine pipeline and making an urgent case for TB vaccines as critical to ending the pandemic. Co-director Lindsay McKenna leads the project's work on TB treatment research and translation, coordinating the Global TB Community Advisory Board (TB CAB) and its work shaping the TB treatment research agenda, including by meeting product sponsors, publishing and presenting position papers advocating to address the unmet needs



TAG and MSF after a “Time for \$5 Campaign” action targeting Danaher/Cepheid TB test prices at the 2023 Union Conference; David Branigan, senior TB project officer is third from left, and TB project co-director, Lindsay McKenna is far right.

of people with XDR-TB, to better balance toxicity and duration in TB treatment research; and to broaden the options for TB prevention and treatment.

As a member of the Supporting, Mobilizing, and Accelerating Research for TB Elimination (SMART4TB) consortium, TAG partnered with three regional CABs representing Africa, Southeast Asia, and Eastern Europe-Central Asia. In June, TAG hosted these CABs for a kickoff workshop in New York City, devising opportunities to shape SMART4TB research priorities to best serve TB community interests. Senior TB project associate Erin McConnell led the development and launch of the SMART4TB CABLab, an online training course to build CAB member skills like reviewing clinical trial protocols and to equip and empower activist partners to engage in research and policy advocacy.

TAG partnered with the IMPAACT network and SMART4TB to advocate for the long overdue end of the systematic exclusion of pregnant individuals from TB research, which has left us without needed evidence for safe and effective cures. TAG coordinated a global task force of TB community leaders, including several women with lived experience undergoing treatment while pregnant to develop a community consensus position paper on how to rightfully incorporate pregnant populations into TB treatment and vaccines research so that they too can share in the benefits of scientific progress.





## PROGRAMS

# HCV PROJECT

The introduction of direct-acting antiretrovirals (DAAs) that cure hepatitis C Virus (HCV) in 2014 has been one of the greatest medical breakthroughs of the 21st Century: HCV is now fully curable in only eight to 12 weeks with these all-oral medicines and with minimal side effects. Unfortunately, a decade later, DAAs are still only reaching a small minority of people living with HCV around the world, and 400,000 people continue to die annually of HCV-related causes.

To better understand what's keeping people living with HCV from accessing needed care, acting HCV project director Joelle Dountio Ofimboudem spent much of early 2023 surveying advocates in low- and middle-income countries (LMICs) to assess HCV programming around the world. The surveys shed light on key gaps, including HCV diagnostic hurdles, limited integration with HIV or STI services, and lack of political leadership on HCV elimination. Dountio Ofimboudem published a policy brief analyzing the findings, *Have a Heart: Save My Liver!: Why Hepatitis C Virus Care Remains Inaccessible*. She presented a poster on the topic at the Conference on Liver Diseases in Africa (COLDA) in Tanzania, which was voted “best poster” by conference participants. The HCV team organized a workshop to convene civil society and policymakers in Brazil and Argentina to discuss country-specific HCV care challenges and strategies to overcome them.

Long-acting technologies (LATs) could eventually help close gaps in care delivery (by streamlining linkage to care and preventing loss-to-follow-up) but only if these interventions are acceptable and accessible. As a partner of the Unitaids-funded LONGEVITY Project, TAG continues to coordinate the Long-Acting Technology Community Advisory Board (LAT CAB) to ensure that LATs currently in the research and development (R&D) pipeline for HCV, TB, and malaria serve the needs and preferences of people affected by these diseases. To ensure this, TAG contributed to the development and implementation of surveys among policy makers, healthcare providers and end users on their attitudes and preferences for LATs in low- and middle-income countries to inform the R&D process and advocacy to generate demand.

The HCV project continues to advocate to overcome barriers to care in the United States, where some 15,000 people die of HCV-related causes each year. TAG contributed to an analysis published by the *Civil Rights Litigation Clearinghouse* setting forth policies to expand HCV testing and treatment in U.S. prisons and jails, advocated for a national HCV elimination program, and published a paper, *Now is the Time for Hepatitis C Virus Elimination*. TAG's HCV and HIV teams jointly hosted a webinar on HCV/HIV comorbidity called *HCV Elimination Among People Living with and at High Risk of HIV: Challenges and Opportunities*, featuring experts and clinicians.



**ABOVE** Joelle with other conference attendees

**UPPER LEFT** Acting HCV director Joelle Dountio Ofimboudem after winning an award for “Best Poster Presentation at the 2023 COLDA Conference, for her presentation: “Have a Heart, Save My Liver”

## PROGRAMS

# POLICY 2023

Ending HIV, TB, and HCV requires action from a range of powerful actors: elected and public officials and agencies at the local, state, and national levels, international normative bodies, funders, and communities. Interfacing with them to advance TAG priorities is the core goal of our policy project.

Last year U.S. and global health policy director Lizzy Lovinger executed an ambitious strategy for 2023, shaping appropriations processes in Congress, formulating research recommendations for federal agencies, and outreach to the U.S. Mission to the United Nations before the High-Level Meeting (HLM) on TB. Keeping all those plates spinning requires productive partnerships with elected officials and their staffs, and civil society allies.

Last March, TAG government relations & policy associate Kendall Martinez-Wright cofacilitated the 2023 TB Survivors Hill Day with the TB Roundtable. This key event included congressional briefings and meetings with key members of Congress to build support for funding increases for TB research and TB programs in the U.S. and internationally. In May, the Policy team facilitated the ACT NOW: END AIDS (ANEA) Capitol Hill advocacy day, convening community-based HIV organizations for meetings across congressional offices demanding that federal funding for HIV programs, including PEPFAR and the Ryan White Care Act, be protected and expanded. Martinez-Wright helped bring together policy stakeholders for workshops on federal hepatitis elimination plans, and how using a cross-disease approach can benefit the fight against both HIV and HCV.

TAG's policy team put considerable energy toward expansion of global commitments to end HIV, TB, and HCV. They represented TAG at multiple UN events, urging delegates to make good on commitments to mobilize resources for TB research and development.



**LEFT** Kendall Martinez-Wright, government relations and policy associate, with fellow TB advocate, Kate O'Brien



**ABOVE** U.S. and global health policy director Lizzy Lovinger (right) outside Sen. Chuck Schumer's office, with staffers from We Are TB and the TB Elimination Alliance.

Lovinger submitted testimony to the UN on Pandemic Prevention, Preparedness, and Response, arguing for increased support for HIV, TB, and HCV to proactively build capacity for responding to future pandemics. Lovinger spearheaded the creation of a working group focused on drug-resistant TB to ensure the disease is incorporated into future UN strategies against AMR.

The policy team spearheads TAG's ongoing dialogue with key federal agencies, such as the National Institute of Allergy and Infectious Diseases (NIAID). Last year, this included the start of a productive relationship with NIAID's newly appointed director, Dr. Jeanne Marrazzo, with whom TAG hopes for a fruitful collaboration moving forward, and with other NIH leaders on expediting research, access, and equity.



# 2023 FINANCIALS

## BALANCE SHEET

### ASSETS

	2023	2022
Cash and cash equivalents	\$1,442,638	\$1,510,735
Unconditional Promises to Give	1,796,031	555,526
Accounts receivable	-	3,756
Prepaid expenses and other current assets	81,142	86,189
Donated artwork	517,139	481,839
Leasehold	723,115	844,900
Security deposit	50,402	50,402
Property and equipment - net	13,565	15,931
<b>TOTAL ASSETS</b>	<b>\$4,624,032</b>	<b>\$3,549,278</b>

### LIABILITIES AND NET ASSETS

#### Liabilities

Accounts payable and accrued expenses	\$74,007	\$38,723
Lease Liability	804,068	892,568
Refundable Advance	134,874	-
<b>Total Liabilities</b>	<b>1,012,949</b>	<b>931,291</b>

#### Net Assets

Without donor restrictions	1,775,039	1,965,644
With donor restrictions	1,836,044	652,343
<b>Total Net Assets</b>	<b>3,611,083</b>	<b>2,617,987</b>

### TOTAL LIABILITIES AND NET ASSETS

**\$4,624,032** **\$3,549,278**

## STATEMENT OF CASH FLOWS

### CASH FLOWS FROM OPERATING ACTIVITIES

	2023	2022
Increase (decrease) in net assets	\$993,096	(\$802,118)
Adjustments to reconcile increase (decrease) in net assets to net cash used by operating activities:		
Non-cash operating lease expense	121,785	119,657
Depreciation	5,564	4,365
Bad Debt Expense	-	18,000
Loss on disposal of equipment	-	190
Loan Forgiveness - Paycheck Protection Program	-	(301,325)
(Increase) decrease in:		
Unconditional promises to give	(1,240,505)	772,924
Accounts receivable	-	(3,756)
Prepaid expenses and other assets	8,803	(13,808)
Donated artwork	(35,300)	(25,900)
Security Deposit	-	-
Increase (decrease) in:		
Accounts payable and accrued expenses	35,284	(4,288)
Lease Liability	(88,500)	(83,744)
Refundable Advance	134,874	-
<b>Net Cash Used by Operating Activities</b>	<b>(64,899)</b>	<b>(319,803)</b>

### CASH FLOWS FROM INVESTING ACTIVITIES

Acquisition of property and equipment	(3,198)	(10,009)
<b>Net Cash Used by Investing Activities</b>	<b>(3,198)</b>	<b>(10,009)</b>


### CASH FLOWS FROM FINANCING ACTIVITIES

Proceeds from loan payable	-	-
Increase (decrease) in cash and cash equivalents	(68,097)	(329,812)
Cash and cash equivalents, beginning of year	1,510,735	1,840,547
<b>CASH AND CASH EQUIVALENTS, END OF YEAR</b>	<b>\$1,442,638</b>	<b>\$1,510,735</b>

## STATEMENT OF ACTIVITIES

	WITHOUT DONOR RESTRICTIONS	WITH DONOR RESTRICTIONS	TOTAL
<b>REVENUE AND OTHER SUPPORT</b>			
Contributions	374,074	4,037,601	4,411,675
Loan forgiveness - Paycheck Protection Program	-	-	-
Federal Relief Program - Employee retention tax credits	-	-	-
Fundraising benefit events	242,151	-	242,151
Less: Direct benefit costs	(37,625)	-	(37,625)
Donated artwork, goods and services	66,554	-	66,554
Art sales, net of cost of goods sold	404	-	404
Other income	43,188	-	43,188
Interest income	9,829	-	9,829
Net assets released from restrictions	2,853,900	(2,853,900)	-
<b>TOTAL REVENUE AND OTHER SUPPORT</b>	<b>3,552,475</b>	<b>1,183,701</b>	<b>4,736,176</b>
<b>EXPENSES</b>			
<b>Program Services</b>			
HIV Program	723,383	-	723,383
Hepatitis C Virus Program	323,533	-	323,533
TB Program	1,558,117	-	1,558,117
U.S. and Global Health Policy	359,670	-	359,670
<b>TOTAL PROGRAM SERVICES</b>	<b>2,964,703</b>	<b>-</b>	<b>2,964,703</b>
<b>Supporting Services</b>			
Management and general	477,045	-	477,045
Fundraising	301,332	-	301,332
<b>TOTAL EXPENSES</b>	<b>3,743,080</b>	<b>-</b>	<b>3,743,080</b>
Increase (decrease) in net assets	(190,605)	1,183,701	993,096
Net assets, beginning of year	1,965,644	652,343	2,617,987
<b>NET ASSETS, END OF YEAR</b>	<b>1,775,039</b>	<b>1,836,044</b>	<b>3,611,083</b>

## FUNCTIONAL EXPENSE SUMMARY





# 2023 CONTRIBUTORS

## \$100,000 OR MORE

The Aurum Institute  
Bill & Melinda Gates Foundation  
Fred Hutchinson Cancer Research Center  
Supporting, Mobilizing, and Accelerating Research for Tuberculosis Elimination (SMART4TB), a cooperative agreement with USAID made possible by the generous support of the American people  
University of Nebraska Medical Center  
ViiV Healthcare

## \$50,000 TO \$99,999

The Debs Foundation; Richard A. and Barbara Knowles Debs; Nicholas Debs; Elizabeth A. Debs  
Housing Works  
Médecins Sans Frontières  
Merck & Co.  
Stop TB Partnership, hosted by UNOPS  
Veterans Affairs Medical Center of Washington DC

## \$10,000 TO \$49,999

amfAR, The Foundation for AIDS Research  
Broadway Cares/Equity Fights AIDS  
Capital Group/Jameel Jiwani  
Fannie & Stephen Kahn Charitable Foundation  
John Voelcker  
Laura A. Morrison  
Nicholas Debs  
Richard Lynn and Joseph Evall  
Robert W. Lennon and Mark Gilrain  
Sally Glenn Williams Fund of The Winston-Salem Foundation  
Weil, Gotshal & Manges LLP

## \$5,000 TO \$9,999

Ivy Kwan Arce and Alex Arce  
Jeffrey Schoenfeld  
JP Morgan Chase Foundation  
Kevin and Neil Goetz/Screen Engine ASI  
Mark Sexton and W. Kirk Wallace

Marta Heflin Foundation  
Michael Stipe  
Mrinal Vikram and Kevin Finnegan/The BLM Fund  
Phyllis Housen  
Rachel B. Tiven and Seth M. Marnin/Superqueer Tzedakah Fund  
Roche Molecular Systems  
The Gendal Family Foundation/Dr. Ellen Gendal and David Gendal  
  
**\$2,500 TO \$4,999**  
Bob Bronzo  
Callen-Lorde Community Health Center  
Christina and Kenneth Hecht  
David Puente  
Dr. Bruce Schackman and Ed Sikov  
Evan Schwartz and Robett Fitterman  
Frank Selvaggi  
Glenn Ligon  
John F. Duane and Mary E. Northridge  
Kelsey Louie  
Mark Harrington

Megan Harrington and  
Jonathan Creighton

Nadine Witkin

Robert Monteleone

Société Générale

Surajkumar, Saurav, Aarav,  
and Keshav Madoori

### **\$1,000 TO \$2,499**

Ama Burnham

Barry Wolf

Benjamin Clay McKnight  
and Jeffrey Perri

Billy O'Callaghan

Bjorn Lee Varella

Blaine Vella

Bruce Pachter

Chase Tucker

Daniel Ptacek

David Corkery

Donna M. Pauldine

Dr. J. Michael McCune III  
and Dr. Karen Kaye  
Smith-McCune

Elizabeth Lovinger and  
Tigist Kassahun

Former NY State Senator  
Thomas K. Duane

Global Health Strategies

Ian Thompson

Jason Kirk and Mark Schatz

Jim Aquino

Joseph Lauretano

Karen Bronzo Rabb and  
Jefferson Rabb

Katherine C. and  
Thomas M. Ash III

Kishani Moreno/GMHC

Lynda M. Dee, Esq.

Mark A. Quigley

Matthew Brown

Meredith Stephens

Mike T. Isbell

Mirla and George Morrison

Noel E.D. Kirnon and  
Michael D. Paley

P. Forrest Williams

Patrick Mouton

Physique 57

Raymond Gallagher

Robert C. Henry

Roland Benton

Sarah Bowden

Steven Armstrong

Winston Layne

### **\$500 TO \$999**

Alan Cumming

Ann Northrop

Babette Krolik and  
Harry Greenwald

Brian Packham

Clifford Richner

Craig Joseph Magaw

Cuong Pham and Thao Hon

David C. Levine

Diane Parrish

Dr. Kelly E. Dooley

Dr. Lawrence Corey/  
Corey Family Trust

Drew Hodges and Peter  
Kukielski

Elaine and Glenn Mealy

Greig Sargeant

Jane Silver

Jay Leitz

John Caldwell and Zane  
Blaney / John and Zane's  
Queer Legacy Fund

Julian McKenna

Kate Lear and  
Dr. Jonathan LaPook

Kathleen and  
Patrick O'Leary

Linda Gattegno Berghoff

Lisa Feldstein

Lousine Shamamian

Lyle Saunders

Mallory McKown

Mariko Takahashi

Mary Ann Chiasson

Meni Melek

Michael Beltran and  
Timothy Ford



Michele Araujo  
Ms. Wendy Wertheimer  
Nicholas Ginsberg  
Paul Dietz  
Peter Zimmer  
Robert Keith Cheek  
Ron Goldberg and  
Joe Chiplock  
Scott Dainton  
Steven Frank  
The Andrew D. Zacks  
Foundation  
Yoon Kook Kim

**\$250 TO \$499**

Bianca Maria Orlando  
Carla Dunn  
Claire Lennon  
Dana Delgado  
Dana Katz  
David France  
David Izbicki  
David Shaw  
Diana Loffredo  
Donna Chacon  
Donna Futterman  
Dr. Amita Gupta  
Dr. Carole D. Mitnick  
Dr. Joel R. Gavriale-Gold  
Dr. John B. Steever  
Dr. Judith D. Auerbach

Dr. Robert H. Remien  
Dustin Duncan  
EJ Wepler  
Elif Ongoren  
Eugene Villani and  
Douglas Reilly  
Friends of Deborah Glick  
Guillermo Chacon  
Jason Schreiber  
Jennifer Summa  
Jim Eigo  
Jonathan Levin  
Joseph J. Ciancaglini  
Joseph McConnell and  
Erik Haagensen  
Joy Episalla and  
Carrie Yamaoka  
Judith Feinberg, M.D.  
Justin Keats  
Kimberly Miller  
Kurt Krohne  
Lauren Houghton  
Leslie Asako Gladsjo  
Linda Monteleone  
Mary and Tim Casey  
Nancy Schultz  
Nick Diamond and  
Keletso Makofane  
Nicole Wright  
Pam Parker  
Patrick McGovern

Paul D.C. Huang  
Paul Kennedy  
Peter Yorgin  
Philip Barker  
Rebecca Jordan-Young  
Rex Bonomelli  
Richard Strange  
Robert Bazell  
Ryan Garson  
Salmaan Keshavjee  
Sarah and Roy Schutzengel  
Shawn Fenwick  
Sheila Reeves  
Sung Woon Kil  
Sunita Viswanath and  
Stephan Shaw  
Virginia Shubert and  
David Sipress  
Wakefield

*TAG would like to thank all of the additional donors not listed here, including those who gave generously to TAG as part of campaigns hosted by PayPal Charitable Giving, Network for Good, and Facebook fundraising campaigns. TAG also received generous Employee Matching Funds from several business giving platforms. Finally, we would like to acknowledge Tamrin Goldberg and the rest of the Moulin Rouge! The Musical Touring Cast for their fundraising efforts on behalf of TAG. We would also like to thank all anonymous donors and those who gave in honor and memory of others.*

# LIMITED ART EDITIONS

Each year at our Research in Action Awards, TAG presents a new, limited edition work of art, generously donated by highly regarded visual artists. In 2023, our beautiful edition was *Entre el cielo y la tierra : 天地之間 東經134度 4分38秒, 北緯34度28分53秒*, by Ivy Kwan Arce. Ivy is now our board president and was a 2021 RIAA honoree.

Speaking about this artwork, Ivy said “Each individualized assemblage includes a personally designed HIV/AIDS legacy shawl that serves as a tangible testament to pivotal cases and manifestos that revolutionized healthcare and science for People with AIDS (PWA). These groundbreaking efforts forged pathways fundamentally changing patient rights and the landscape of healthcare both locally and globally.”




We maintain an inventory of many of the editions — including Ivy’s 2023 piece — for sale to the public, and all of the proceeds go to benefit TAG’s work. If you’re interested in purchasing an edition, or learning more about the available editions, you can find detailed information online:

<https://www.treatmentactiongroup.org/support-us/limited-art-editions/>



2023's *Entre el cielo y la tierra : 天地之間 東經134度 4分38秒, 北緯34度28分53秒*, by Ivy Kwan Arce





<https://www.treatmentactiongroup.org/support-us/limited-art-editions/>

# ABOUT TAG

Treatment Action Group (TAG) is an independent, activist, and community-based research and policy think tank committed to racial, gender, and LGBTQ+ equity; social justice, and liberation, fighting to end HIV, TB, and HCV.

TAG catalyzes open collective action by affected communities, scientists, and policymakers to ensure that all people living with or impacted by HIV, TB, or HCV — especially communities of color and other marginalized communities experiencing inequities — receive lifesaving prevention, diagnosis, treatment, care, and information.

We are science-based activists working to expand and accelerate vital research and effective community engagement with research and policy institutions for an end to the HIV, TB, and HCV pandemics.

## SUPPORT TAG

Supporting TAG is an invaluable investment in advocacy efforts aimed at putting an end to the devastating epidemics of HIV, TB, and HCV. Our dedicated and highly respected team of professionals, despite being small in number, maximizes the impact of your support. Every donation to TAG brings us closer to achieving our goal of eradicating these epidemics and improving equitable access for all. Please join us in our mission to create a healthier world for everyone.

There are many ways you can support TAG — two of the most obvious are our annual Research in Action Awards and you can purchase a TAG Limited Art Edition. But there are other ways to help us. You can become a **monthly donor**, make a **planned gift**, make a **gift of stock**, encourage friends and family to **make a donation in your honor** on special occasions, try to **get your organization involved with TAG**, support TAG through **Donor Advised Funds**, or you could even **join TAG's board**!

### TAG'S WORK IS BASED ON THESE CORE VALUES:

- Science- and Evidence-Based Approaches
- Activism
- Openness
- Collaboration
- Respect
- Nurturing Environments
- Power Sharing
- Centering Affected Community Voices
- Health
- Human Rights
- Access for All/  
Distributive Justice
- Racial Justice

# TAG

Treatment Action Group

TAG is a nonprofit,  
tax-exempt 501(c)(3)  
organization.  
EIN 13-3624785





## 2024 BOARD OF DIRECTORS

Ivy Kwan Arce | **PRESIDENT**

Mrinal Vikram | **SECRETARY**

Laura Morrison | **INTERIM TREASURER**

Barbara Hughes | **BOARD PRESIDENT EMERITUS**

Jim Aquino Dr. Stefan Goldberg

Bob Bronzo Jameel Jiwani

Ama Burnham Robert W. Lennon

Julian Chung Robert Monteleone

Nick Debs David Puente

Joy Episalla Karl Schmid

Kevin Goetz Tanya Walker

## SAVE THE DATE



October 17, 2024

At the Angel Orensanz Foundation  
172 Norfolk Street, New York, NY 10002

*in person and streaming*

[HTTPS://WWW.TREATMENTACTIONGROUP.ORG/RIAA](https://www.treatmentactiongroup.org/riaa)

## 2024 STAFF

Mark Harrington  
**EXECUTIVE DIRECTOR**

Cheriko Boone  
**HIV PROJECT DIRECTOR**

David Branigan  
**TB PROJECT OFFICER**

Antar T. Bush  
**HIV COMMUNITY  
ENGAGEMENT MANAGER**

Joelle Dountio Ofimboudem  
**ACTING HCV PROJECT DIRECTOR**

Mike Frick  
**TB PROJECT CO-DIRECTOR**

Christopher George  
**DIRECTOR OF FINANCE**

Sabrina Guerrero-Morris  
**DIRECTOR OF OPERATIONS  
AND HUMAN RESOURCES**

Richard Jefferys  
**BASIC SCIENCE, VACCINES,  
AND CURE PROJECT DIRECTOR**

Lucas Kade  
**GRANTS MANAGER**

Jason Kirk  
**CHIEF OPERATING OFFICER**

De'Ashia Lee  
**ACT NOW END AIDS (ANEA)  
COALITION DIRECTOR**

Elizabeth Lovinger  
**U.S. AND GLOBAL HEALTH  
POLICY DIRECTOR**

Kendall Martinez-Wright  
**GOVERNMENT RELATIONS  
AND POLICY ASSOCIATE**

Joseph McConnell  
**ADMINISTRATOR**

Erin McConnell  
**SENIOR TB PROJECT ASSOCIATE**

Lindsay McKenna  
**TB PROJECT CO-DIRECTOR**

Natalie Shure  
**PROGRAMMATIC COMMUNICATIONS  
COORDINATOR**

Dorrit Walsh  
**COMMUNICATIONS DIRECTOR**



## **Treatment Action Group**

90 Broad Street, Suite 2503

New York, NY 10004

Tel 212.253.7922

[tag@treatmentactiongroup.org](mailto:tag@treatmentactiongroup.org)

[www.treatmentactiongroup.org](http://www.treatmentactiongroup.org)

TAG is a nonprofit, tax-exempt  
501(c)(3) organization. EIN 13-3624785